These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 14693310

  • 1. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
    O'Connor P, CHAMPS.
    Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
    [Abstract] [Full Text] [Related]

  • 2. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP, Kollman C, O'Connor P, Murray TJ, Simon J, Arnold D, Bakshi R, Weinstock-Gutman B, Brod S, Cooper J, Duquette P, Eggenberger E, Felton W, Fox R, Freedman M, Galetta S, Goodman A, Guarnaccia J, Hashimoto S, Horowitz S, Javerbaum J, Kasper L, Kaufman M, Kerson L, Mass M, Rammohan K, Reiss M, Rolak L, Rose J, Scott T, Selhorst J, Shin R, Smith C, Stuart W, Thurston S, Wall M, CHAMPIONS Study Group.
    Neurology; 2006 Mar 14; 66(5):678-84. PubMed ID: 16436649
    [Abstract] [Full Text] [Related]

  • 3. Early MRI activity predicts treatment nonresponse with intramuscular interferon beta-1a in clinically isolated syndrome.
    Kinkel RP, Simon JH, O'Connor P, Hyde R, Pace A.
    Mult Scler Relat Disord; 2014 Nov 14; 3(6):712-9. PubMed ID: 25891550
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses.
    Beck RW, Chandler DL, Cole SR, Simon JH, Jacobs LD, Kinkel RP, Selhorst JB, Rose JW, Cooper JA, Rice G, Murray TJ, Sandrock AW.
    Ann Neurol; 2002 Apr 14; 51(4):481-90. PubMed ID: 11921054
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
    Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, Maurer SL, Riester K, Davar G, Dawson K, Sandrock A, Avonex CIDP Study Group.
    Neurology; 2010 Feb 23; 74(8):651-7. PubMed ID: 20177118
    [Abstract] [Full Text] [Related]

  • 11. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
    Phillips JT, Fox E, Grainger W, Tuccillo D, Liu S, Deykin A.
    BMC Neurol; 2011 Oct 14; 11():126. PubMed ID: 21999176
    [Abstract] [Full Text] [Related]

  • 12. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
    Cochrane Database Syst Rev; 2017 Apr 25; 4(4):CD012200. PubMed ID: 28440858
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, Casset-Semanaz F, Hennessy B, Moraga MS, Rocak S, Stubinski B, Kappos L.
    Lancet Neurol; 2012 Jan 25; 11(1):33-41. PubMed ID: 22146409
    [Abstract] [Full Text] [Related]

  • 18. Ten-year follow-up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial.
    Simon JH, Kinkel RP, Kollman C, O'Connor P, Fisher E, You X, Hyde R, CHAMPIONS Investigators Group.
    Mult Scler; 2015 Apr 25; 21(4):415-22. PubMed ID: 25344370
    [Abstract] [Full Text] [Related]

  • 19. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study).
    Galetta SL.
    J Neuroophthalmol; 2001 Dec 25; 21(4):292-5. PubMed ID: 11756862
    [Abstract] [Full Text] [Related]

  • 20. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X, Chin PS, Hashmonay R, Zahur Islam M, Cutter G.
    Contemp Clin Trials; 2015 Mar 25; 41():69-74. PubMed ID: 25545026
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.